Ucb Sa Stock Performance
| UCBJF Stock | USD 174.00 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 0.15, which indicates not very significant fluctuations relative to the market. As returns on the market increase, UCB SA's returns are expected to increase less than the market. However, during the bear market, the loss of holding UCB SA is expected to be smaller as well. At this point, UCB SA has a negative expected return of -0.0285%. Please make sure to validate UCB SA's variance, as well as the relationship between the maximum drawdown and rate of daily change , to decide if UCB SA performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days UCB SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable forward-looking indicators, UCB SA is not utilizing all of its potentials. The newest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 1.3 B | |
| Total Cashflows From Investing Activities | -487 M | |
| Free Cash Flow | 1.1 B |
UCB |
UCB SA Relative Risk vs. Return Landscape
If you would invest 17,850 in UCB SA on September 12, 2024 and sell it today you would lose (450.00) from holding UCB SA or give up 2.52% of portfolio value over 90 days. UCB SA is currently producing negative expected returns and takes up 1.5301% volatility of returns over 90 trading days. Put another way, 13% of traded pink sheets are less volatile than UCB, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
UCB SA Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for UCB SA's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as UCB SA, and traders can use it to determine the average amount a UCB SA's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0186
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | UCBJF |
Estimated Market Risk
| 1.53 actual daily | 13 87% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average UCB SA is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of UCB SA by adding UCB SA to a well-diversified portfolio.
UCB SA Fundamentals Growth
UCB Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of UCB SA, and UCB SA fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on UCB Pink Sheet performance.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 17.07 B | |||
| Shares Outstanding | 189.96 M | |||
| Price To Earning | 17.62 X | |||
| Price To Book | 1.52 X | |||
| Price To Sales | 2.50 X | |||
| Revenue | 5.78 B | |||
| EBITDA | 1.59 B | |||
| Cash And Equivalents | 515 M | |||
| Cash Per Share | 2.71 X | |||
| Total Debt | 1.97 B | |||
| Debt To Equity | 0.34 % | |||
| Book Value Per Share | 46.94 X | |||
| Cash Flow From Operations | 1.55 B | |||
| Earnings Per Share | 4.90 X | |||
| Total Asset | 14.21 B | |||
| Retained Earnings | 3 B | |||
| Current Asset | 2.46 B | |||
| Current Liabilities | 2.71 B | |||
About UCB SA Performance
By analyzing UCB SA's fundamental ratios, stakeholders can gain valuable insights into UCB SA's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if UCB SA has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if UCB SA has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. Ucb SA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 8600 people.Things to note about UCB SA performance evaluation
Checking the ongoing alerts about UCB SA for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for UCB SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| UCB SA generated a negative expected return over the last 90 days | |
| About 38.0% of the company outstanding shares are owned by insiders |
- Analyzing UCB SA's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether UCB SA's stock is overvalued or undervalued compared to its peers.
- Examining UCB SA's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating UCB SA's management team can have a significant impact on its success or failure. Reviewing the track record and experience of UCB SA's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of UCB SA's pink sheet. These opinions can provide insight into UCB SA's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for UCB Pink Sheet analysis
When running UCB SA's price analysis, check to measure UCB SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy UCB SA is operating at the current time. Most of UCB SA's value examination focuses on studying past and present price action to predict the probability of UCB SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move UCB SA's price. Additionally, you may evaluate how the addition of UCB SA to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |